Novonesis opens the weekend with a clear biotech strategy, shares trade on Xetra

By Stefan Krüger, Long-Term & Business Model desk. Reviewed prior to publication on 2026-06-27, 15:10.

Novonesis (DK0060336014) is attracting long-term oriented investors with its focus on industrial enzymes and biosolutions, while its B shares trade in Europe via Xetra in the biotechnology segment. The group stands as a peer to specialists such as Novozymes and Chr. Hansen in the wider Nordic bioscience cluster.

Operational focus in biosolutions

Novonesis emerged from the combination of Novozymes and Chr. Hansen, building a broad portfolio of enzyme and microbial solutions for industries ranging from food and beverages to agriculture and household care, according to company information.Novonesis investor relations overview The company positions itself as a provider of high-value biosolutions that help customers improve yields, reduce resource use and meet sustainability targets.Novonesis investor relations overview

Industrial enzyme producers like Novonesis compete in the global biotechnology field with players such as Dutch group DSM-Firmenich and US-based Danaher in selected application niches, particularly in food ingredients and industrial bioprocessing. The business model relies on long-term partnership contracts and recurring revenue from consumable solutions, which typically leads to relatively resilient cash flows compared with more cyclical chemical producers.

Strategy and sector positioning

Within the European biotech landscape, Novonesis stands alongside enzyme and bioscience peers such as Novozymes and specialty ingredients producers that focus on sustainable solutions for agriculture and food manufacturing. The company aims to expand its reach in biostimulants and microbials, segments that MarketsandMarkets expects to reach a global market size of 8.77 billion dollars by 2031, highlighting the growth potential for targeted biological products.

Biotechnology firms with a focus on industrial applications often present a different risk profile than pure-play drug developers, as their revenues are supported by industrial demand and long-term supply contracts. For Novonesis, the integration of enzyme and microbial technologies allows the group to address customer needs across several value chains, including dairy, baking, plant-based foods and crop protection solutions, providing multiple avenues for organic growth.

The products behind the stock

Novonesis generates revenue primarily through enzyme and microbial solutions used in industries such as food and beverages, agriculture and household care, with representative products including baking enzymes and dairy cultures for improved texture and shelf life, as described by the company.Novonesis investor relations overview These biosolutions are typically sold to industrial customers under long-term contracts, contributing to recurring revenue streams.

Where the shares trade today

The Novonesis B shares (DK0060336014) are listed in Europe with trading on Xetra, where they recently quoted around 54.32 euros, with a bid-ask spread between 54.32 and 54.44 euros. The listing places the company within the biotechnology sector segment on the German venue.

Disclaimer: This article provides factual information on Novonesis and its shares and does not contain investment advice, recommendations or price targets. All data are based on sources believed to be reliable at the time of publication but may change over time.